Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • All Public Company
      • English-only
      • News Releases Overview

      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
      • Multimedia Gallery Overview

      • Trending Topics

      • All Trending Topics
  • Business & Money
      • Auto & Transportation

      • All Automotive & Transportation
      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • Auto & Transportation Overview

      • View All Auto & Transportation

      • Business Technology

      • All Business Technology
      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • Business Technology Overview

      • View All Business Technology

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Financial Services & Investing

      • All Financial Services & Investing
      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • Financial Services & Investing Overview

      • View All Financial Services & Investing

      • General Business

      • All General Business
      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • General Business Overview

      • View All General Business

  • Science & Tech
      • Consumer Technology

      • All Consumer Technology
      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • Consumer Technology Overview

      • View All Consumer Technology

      • Energy & Natural Resources

      • All Energy
      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • Energy & Natural Resources Overview

      • View All Energy & Natural Resources

      • Environ­ment

      • All Environ­ment
      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • Environ­ment Overview

      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • All Heavy Industry & Manufacturing
      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • Heavy Industry & Manufacturing Overview

      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • All Telecomm­unications
      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • Telecomm­unications Overview

      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • All Consumer Products & Retail
      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • Consumer Products & Retail Overview

      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Health

      • All Health
      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • Health Overview

      • View All Health

      • Sports

      • All Sports
      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • Sports Overview

      • View All Sports

      • Travel

      • All Travel
      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • Travel Overview

      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • All Policy & Public Interest
      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • Policy & Public Interest Overview

      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • All People & Culture
      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • People & Culture Overview

      • View All People & Culture

      • In-Language News

      • Arabic
      • español
      • português
      • Česko
      • Danmark
      • Deutschland
      • España
      • France
      • Italia
      • Nederland
      • Norge
      • Polska
      • Portugal
      • Россия
      • Slovensko
      • Suomi
      • Sverige
  • Explore Our Platform
  • Plan Campaigns
  • Create with AI
  • Distribute Press Releases
  • Amplify Content
  • All Products
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Hamburger menu
  • PR Newswire: news distribution, targeting and monitoring
  • Send a Release
    • ALL CONTACT INFO
    • Contact Us

      888-776-0942
      from 8 AM - 10 PM ET

  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • News in Focus
    • Browse All News
    • Multimedia Gallery
    • Trending Topics
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • Explore Our Platform
  • Plan Campaigns
  • Create with AI
  • Distribute Press Releases
  • Amplify Content
  • All Products
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS

Upsher-Smith's Vogelxo™ (Testosterone) Gel 1% (Tubes and Packets) Receives AB-Rating To Testim® From FDA

FDA's Orange Book Updated to Reflect New Vogelxo™ Rating

Upsher-Smith Laboratories, Inc.

News provided by

Upsher-Smith Laboratories, Inc.

Feb 10, 2015, 12:11 ET

Share this article

Share toX

Share this article

Share toX

MAPLE GROVE, Minn., Feb. 10, 2015 /PRNewswire/ -- Upsher-Smith Laboratories, Inc., (Upsher-Smith) today announced that it has received an AB (therapeutic equivalent) rating from the U.S. Food and Drug Administration (FDA) for its previously-approved Vogelxo™ (testosterone) gel 1% unit-dose tubes and packets. FDA determined that Vogelxo™ is therapeutically equivalent to Testim® (testosterone gel) and can be substituted with the expectation that it will produce the same clinical effects and safety profile as Testim® when used in accordance with the conditions specified in the labeling.

Upsher-Smith's Vogelxo™ and its authorized generic Testosterone Gel 1% are prescription medicines used to treat adult males who have low or no testosterone and with conditions associated with low or no testosterone. They provide once-daily dosing with 24-hour transdermal delivery of testosterone and are available in three convenient configurations: unit-dose tubes and packets and metered-dose pumps. Upsher-Smith's Testosterone Gel is the first and only generic transdermal testosterone replacement therapy (TRT) to be available in three configurations.

"We are pleased that Vogelxo™ tubes and packets and, by extension, its authorized generic Testosterone Gel 1% tubes and packets, received an AB rating," said Rusty Field, Chief Commercial Officer, Upsher-Smith.  "At Upsher-Smith, we strive to bring high-quality medications to market that are more affordable and accessible to patients."

IMPORTANT SAFETY INFORMATION

Vogelxo™ and Testosterone Gel are controlled substances (CIII) because they contain testosterone, which can be a target for people who abuse prescription medicines. Keep your Vogelxo or Testosterone Gel in a safe place to protect it. Never give your Vogelxo or Testosterone Gel to anyone else, even if they have the same symptoms you have. Selling or giving away this medicine may harm others and it is against the law.

What is the most important information I should know about Vogelxo or Testosterone Gel? Early signs and symptoms of puberty have happened in young children who were accidentally exposed to testosterone through contact with men using Vogelxo or Testosterone Gel. Signs and symptoms of early puberty in a child may include:

  • enlarged penis or clitoris
  • early development of pubic hair
  • increased erections or sex drive
  • aggressive behavior

It is important that you apply Vogelxo or Testosterone Gel exactly as your healthcare provider tells you to. Vogelxo and Testosterone Gel can transfer from your body to others. Women and children should avoid contact with the unwashed or unclothed area where Vogelxo or Testosterone Gel has been applied. If a woman or child makes contact with the Vogelxo or Testosterone Gel application area, that area on the woman or child should be washed well with soap and water right away.

Stop using Vogelxo or Testosterone Gel and call your healthcare provider right away if you see any signs and symptoms in a child or a woman that may have occurred through accidental exposure to Vogelxo or Testosterone Gel.

  • Signs and symptoms of exposure to Vogelxo or Testosterone Gel in children may include: enlarged penis or clitoris; early development of pubic hair; increased erections or sex drive; aggressive behavior
  • Signs and symptoms of exposure to Vogelxo or Testosterone Gel in women may include: changes in body hair; a large increase in acne

To lower the risk of transfer of Vogelxo or Testosterone Gel from your body to others, you should follow these important instructions:

  • Apply Vogelxo or Testosterone Gel only to the areas of your shoulders and upper arms that will be covered by a short sleeve T-shirt. 
  • Wash your hands right away with soap and water after applying Vogelxo or Testosterone Gel.
  • After the gel has dried, cover the application area with clothing. Keep the area covered until you have washed the application area well or have showered.
  • If you expect to have skin-to-skin contact with another person, first wash the application area well with soap and water.

Do not use Vogelxo or Testosterone Gel if you: have breast cancer, or have or might have prostate cancer.

Vogelxo and Testosterone Gel are not meant for use in women. Do not use Vogelxo or Testosterone Gel if you are pregnant or may become pregnant or are breastfeeding. Vogelxo and Testosterone Gel may harm your unborn or breastfeeding baby. Women who are pregnant or who may become pregnant should avoid contact with the area of skin where Vogelxo or Testosterone Gel has been applied.

Before you use Vogelxo or Testosterone Gel, tell your healthcare provider if you: have breast cancer; have or might have prostate cancer; have urinary problems due to an enlarged prostate; have heart problems; have liver or kidney problems; have problems breathing while you sleep (sleep apnea); or have any other medical conditions.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Vogelxo and Testosterone Gel and certain other medicines you take can affect each other. Especially, tell your healthcare provider if you take: insulin, medicines that decrease blood clotting, or corticosteroids.

It is important that you apply Vogelxo or Testosterone Gel exactly as your healthcare provider tells you to. Your healthcare provider will tell you how much Vogelxo or Testosterone Gel to apply and when to apply it. Your healthcare provider may change your Vogelxo or Testosterone Gel dose. Do not change your Vogelxo or Testosterone Gel dose without talking to your healthcare provider. Vogelxo and Testosterone Gel are to be applied only to the areas of your shoulders and upper arms that will be covered by a short sleeve t-shirt. Do not apply Vogelxo or Testosterone Gel to any other parts of your body such as your penis, scrotum, or stomach area (abdomen).

Vogelxo and Testosterone Gel are flammable until dry. Let Vogelxo or Testosterone Gel dry before smoking or going near an open flame. 

Vogelxo and Testosterone Gel can cause serious side effects including:

  • If you already have enlargement of your prostate gland your signs and symptoms can get worse while using Vogelxo or Testosterone Gel. This can include: increased urination at night; trouble starting your urine stream; having to pass urine many times during the day; having an urge that you have to go to the bathroom right away; having a urine accident; being unable to pass urine or weak urine flow.
  • Possible increased risk of prostate cancer. Your healthcare provider should check you for prostate cancer or any other prostate problems before you start and while you use Vogelxo or Testosterone Gel.
  • Blood clots in your legs or lungs. Symptoms of a blood clot in your legs can include leg pain, swelling or redness. Symptoms of a blood clot in your lungs can include difficulty breathing or chest pain.
  • In large doses Vogelxo and Testosterone Gel may lower your sperm count.
  • Swelling of your ankles, feet, or body, with or without heart failure.  
  • Enlarged or painful breasts.
  • Having problems breathing while you sleep (sleep apnea).

Call your healthcare provider right away if you have any of the serious side effects listed above.

The most common side effects of Vogelxo and Testosterone Gel include: skin irritation where Vogelxo or Testosterone Gel are applied; increased red blood cell count; headache; and increased blood pressure.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

This safety information is not all-inclusive.  For more information, talk to your health care provider and read the Medication Guide for patients and the Full Prescribing Information, including the Boxed Warning regarding the risk of transfer to others.  You can also visit www.upsher-smith.com or call 1-888-650-3789.

About Upsher-Smith

Upsher-Smith Laboratories, Inc., founded in 1919, is a growing pharmaceutical company dedicated to its mission of Advancing Pharmacotherapy. Improving Life™.  With capabilities ranging from early-stage research to delivering on-market products, Upsher-Smith is committed to offering quality products that enable people to live life to its greatest potential.  Upsher-Smith's approach to product development and partnering has resulted in a broad range of both branded and generic therapeutic solutions to address patients' needs.  The Company has a particular focus on developing therapies for people living with central nervous system (CNS) conditions, such as seizure disorders, and has a robust pipeline of promising CNS compounds in various stages of development.  For more information, visit www.upsher-smith.com.

Vogelxo is a trademark of Upsher-Smith Laboratories, Inc.

Testim is a registered trademark of Auxilium Pharmaceuticals, Inc.

Logo- http://photos.prnewswire.com/prnh/20130520/NY17281LOGO

SOURCE Upsher-Smith Laboratories, Inc.

Related Links

http://www.upsher-smith.com

21%

more press release views with 
Request a Demo

Modal title

Contact PR Newswire

  • Call PR Newswire at 888-776-0942
    from 8 AM - 9 PM ET
  • Chat with an Expert
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices

Products

  • For Marketers
  • For Public Relations
  • For IR & Compliance
  • For Agency
  • All Products

About

  • About PR Newswire
  • About Cision
  • Become a Publishing Partner
  • Become a Channel Partner
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Italy
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United Kingdom
  • Vietnam

My Services

  • All New Releases
  • Platform Login
  • ProfNet
  • Data Privacy

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Platform Login
  • ProfNet
Call PR Newswire at
888-776-0942
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookies
Copyright © 2025 Cision US Inc.